The numbers are staggering. Alzheimer disease (AD) affected 57 million people globally in 2019, a figure projected to reach 153 million by 2050. The cumulative economic burden between 2020 and 2050 exceeds INT$14 trillion. Dementia is already the fifth leading cause of death worldwide, claiming 2.4 million lives in 2016, with 6.4 million disability-adjusted life years attributable to modifiable risk factors alone.
For decades, the sleep disruptions that accompany Alzheimer disease were regarded as collateral damage, an unfortunate but secondary consequence of neuronal loss. A mounting body of evidence has turned that assumption on its head. A new narrative review published in Neuroprotection by Singh, Pigazzani, and Manfredini synthesizes 109 studies to argue that circadian disruption is not merely a symptom of Alzheimer disease, it is an active driver of its pathology. And that insight opens the door to a previously overlooked class of interventions: chronotherapies that work with the body’s internal clock rather than against it.
The Molecular Clock-AD Connection
The argument rests on detailed molecular biology. At the heart of the circadian system sits a transcription-translation feedback loop driven by core clock genes including BMAL1, CLOCK, PER, and CRY. These genes regulate not just sleep-wake timing but fundamental cellular processes throughout the body and brain. When the clock breaks, it breaks more than sleep.
The review identifies several specific molecular bridges between circadian disruption and Alzheimer pathology. The BMAL1-SIRT1 pathway, when disrupted, impairs the brain’s oxidative stress response and proteostasis, allowing damaged proteins to accumulate. The NF-kB-NLRP3 inflammasome pathway is subject to circadian gating, meaning its inflammatory output varies rhythmically across the day. When the clock goes silent, that gate falls open, amplifying neuroinflammation unchecked. Loss of PER2-mediated antioxidant signaling further compromises neuronal resilience.
Circadian genes also coordinate genome maintenance and cell cycle timing. Disruption at this level may accelerate the DNA damage and cellular senescence that characterize the aging brain. And at the systems level, desynchronization between the central pacemaker in the suprachiasmatic nucleus (SCN) and regional brain clocks disrupts synaptic plasticity and memory consolidation, the very processes that falter earliest in Alzheimer disease.
Glial Cells as New Players
Perhaps the most novel territory the review covers is the role of glial cells in circadian-AD crosstalk. Astrocytes, long regarded as support cells, turn out to modulate SCN neuronal firing through intrinsic calcium rhythmicity. When astrocyte circadian function is disrupted, sleep fragmentation, neuroinflammation, and cognitive decline follow.
Microglia, the brain’s resident immune cells, operate on their own circadian metabolic cycles that regulate glycolysis, mitochondrial function, and NAD+ redox balance. When these cycles fall out of alignment with the external light-dark cycle, microglia shift toward a pro-inflammatory state. Amyloid clearance declines and inflammatory output rises, accelerating the very pathology they might otherwise contain.
Strikingly, the review reports that tau pathology accumulates within both SCN neurons and glial cells, directly compromising clock gene expression. This creates a vicious feedback loop: tau disrupts the clock, and the broken clock accelerates tau spread.
The bidirectional relationship extends beyond the brain. Circadian misalignment disrupts gut microbiota rhythmicity, driving systemic inflammation through the gut-brain axis. Obstructive sleep apnea and non-dipper hypertension, both common comorbidities in Alzheimer patients, impair the blood-brain barrier and deliver intermittent hypoxia, supercharging neuroinflammation. The mTOR pathway, a central node linking metabolism to aging, is dysregulated on both sides of the circadian-AD equation.
Chronotherapeutic Strategies
The clinical payoff of this framework is a suite of interventions that leverage the circadian system rather than fight it. The review catalogs five emerging strategies.
Melatonin receptor agonists remain the most studied. Beyond improving sleep continuity, melatonin may slow cognitive decline through its antioxidant and anti-inflammatory effects, though the evidence base remains mixed. Light therapy, specifically morning bright light exposure timed to the patient’s circadian phase, can reinforce the SCN’s weakened signal and improve sleep-wake consolidation.
Time-restricted feeding, an intervention borrowed from metabolic health research, is associated with lower amyloid-beta deposition and reduced systemic inflammation in early studies. By confining food intake to an 8- to 10-hour window, the approach reinforces peripheral clock rhythms that otherwise drift in Alzheimer disease.
Dual orexin receptor antagonists (DORAs), a newer class of sleep medications, are emerging as promising targets precisely because they modulate the wake-promoting system without the safety concerns of traditional sedatives. On the horizon, circadian-aligned drug delivery systems aim to time the administration of existing Alzheimer therapies to coincide with optimal endogenous rhythms, potentially improving efficacy and reducing side effects.
Why It Matters
The review is a narrative synthesis, not a systematic meta-analysis, and the authors acknowledge potential selection bias. But its power lies in drawing together strands of evidence that have developed largely in parallel: molecular clock biology, glial neuroscience, sleep medicine, and Alzheimer therapeutics.
If circadian disruption drives Alzheimer pathology rather than merely accompanying it, then restoring circadian function becomes a disease-modifying strategy, not a palliative one. The review points toward a future where chronoepigenetics, glial clock restoration, and clock-gated anti-inflammatory approaches join the therapeutic arsenal alongside amyloid and tau-targeted drugs. The takeaway for clinicians and researchers alike is that the clock may be one of the most underappreciated targets in Alzheimer research. It is time to set it right.
Source
Singh B, Pigazzani F, Manfredini R. Circadian disruption in Alzheimer disease: mechanisms and chronotherapeutic strategies. Neuroprotection. 2026 Jul 16. DOI: 10.1002/nep3.70046. PMCID: PMC13398922. PMID: 42499341.